Skip to content

Dispensing Evaluation of Printed Etafilcon A With Polyvinylpyrrolidone (PVP)

Dispensing Evaluation of Printed Etafilcon A With Polyvinylpyrrolidone (PVP) Contact Lenses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01180777
Enrollment
95
Registered
2010-08-12
Start date
2010-07-01
Completion date
2010-08-01
Last updated
2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

The purpose of this study is to evaluate the lens fit (mechanical and cosmetic lens fit) of the printed etafilcon A with polyvinylpyrrolidone (PVP).

Interventions

DEVICEetafilcon A (A)

Daily wear contact lens

DEVICEetafilcon A (B)

Daily wear contact lens

DEVICEetafilcon A (C)

Daily wear contact lens

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

1. The subject must be at least 18 years of age and less than 40 years of age. 2. The subject must be a light eye Caucasian female habitual soft contact lens wearer. 3. The subject must be concept acceptors for cosmetic and/or limbal ring lenses. A concept screening questionnaire will be used and top 3 box (in 5-point scale) is eligible. 4. The subject must have no known ocular or systemic allergies that might interfere with contact lens wear. 5. The subject must have no known systemic disease, or need for medication, which might interfere with contact lens wear. 6. The subject's optimal vertexed spherical equivalent distance correction must be between -1.00 and - 5.00D. 7. Any cylinder power must be ≤ -0.75D. 8. The subject must have visual acuity best correctable to 20/25+3 or better for each eye. 9. The subject must have normal eyes (no ocular medications or ocular infection of any type). 10. The subject must read and sign the Statement of Informed Consent. 11. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.

Exclusion criteria

1. Ocular or systemic allergies or disease which might interfere with contact lens wear. 2. Systemic disease or use of medication which might interfere with contact lens wear. 3. Clinically significant (grade 3 or worse) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear. 4. Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear. 5. Any ocular infection. 6. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear. 7. Any color deficiencies - to the best of the subject's knowledge. 8. Pregnancy or lactation. 9. Diabetes. 10. Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease (e.g. HIV). 11. Habitual contact lens type is toric, multifocal, or is worn as extended wear.

Design outcomes

Primary

MeasureTime frameDescription
Lens Fit Acceptance10-15 minutes post lens fitLens fit acceptance (whether acceptable or unacceptable) was assessed by the Investigator at dispensing.

Secondary

MeasureTime frameDescription
Binocular Snellen Visual Acuity (VA)10-15 minutes post lens fitBinocular Snellen VA was assessed at dispensing by Investigator using a Snellen vision chart. Subjects were analyzed based on their performance on a Snellen Vision chart exam in the study lenses in an effort to measure how well the lenses perform for vision correction.
Corneal StainingAfter 6-9 days of lens wearCorneal staining type was graded in a 5-point scale over the 5 corneal regions by Investigator using a slit lamp; 0=none, 1=trace, 2=mild, 3=moderate, and 4=severe. Maximum grade of corneal staining type over the 5 corneal regions was categorized either absence or presence of corneal staining for the analysis.

Countries

United States

Participant flow

Recruitment details

This study was an eight-site, randomized, 4-visit, bilateral crossover, dispensing trial.

Pre-assignment details

Of those 95 enrolled subjects in this study, 3 did not meet the eligibility criteria, 6 prematurely discontinued from the study, and 6 excluded from the analysis due to protocol deviations.

Participants by arm

ArmCount
All Subjects
Subjects were to wear all three lenses over the course of the study.
95
Total95

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event1
Overall StudyLost to Follow-up1
Overall StudyPoor lens fit4
Overall StudyProtocol Violation6

Baseline characteristics

CharacteristicAll Subjects
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
95 Participants
Region of Enrollment
United States
95 participants
Sex: Female, Male
Female
95 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 95
serious
Total, serious adverse events
1 / 95

Outcome results

Primary

Lens Fit Acceptance

Lens fit acceptance (whether acceptable or unacceptable) was assessed by the Investigator at dispensing.

Time frame: 10-15 minutes post lens fit

Population: All subjects who successfully completed the study.

ArmMeasureGroupValue (NUMBER)
Etafilcon A (A)Lens Fit AcceptanceAcceptable158 eyes
Etafilcon A (A)Lens Fit AcceptanceUnacceptable0 eyes
Etafilcon A (B)Lens Fit AcceptanceAcceptable158 eyes
Etafilcon A (B)Lens Fit AcceptanceUnacceptable2 eyes
Etafilcon A (C)Lens Fit AcceptanceAcceptable157 eyes
Etafilcon A (C)Lens Fit AcceptanceUnacceptable0 eyes
Secondary

Binocular Snellen Visual Acuity (VA)

Binocular Snellen VA was assessed at dispensing by Investigator using a Snellen vision chart. Subjects were analyzed based on their performance on a Snellen Vision chart exam in the study lenses in an effort to measure how well the lenses perform for vision correction.

Time frame: 10-15 minutes post lens fit

Population: All subjects who successfully completed the study.

ArmMeasureGroupValue (NUMBER)
Etafilcon A (A)Binocular Snellen Visual Acuity (VA)20/1542 participants
Etafilcon A (A)Binocular Snellen Visual Acuity (VA)20/2036 participants
Etafilcon A (B)Binocular Snellen Visual Acuity (VA)20/1539 participants
Etafilcon A (B)Binocular Snellen Visual Acuity (VA)20/2039 participants
Etafilcon A (C)Binocular Snellen Visual Acuity (VA)20/1545 participants
Etafilcon A (C)Binocular Snellen Visual Acuity (VA)20/2033 participants
Secondary

Corneal Staining

Corneal staining type was graded in a 5-point scale over the 5 corneal regions by Investigator using a slit lamp; 0=none, 1=trace, 2=mild, 3=moderate, and 4=severe. Maximum grade of corneal staining type over the 5 corneal regions was categorized either absence or presence of corneal staining for the analysis.

Time frame: After 6-9 days of lens wear

Population: All subjects who successfully completed the study.

ArmMeasureGroupValue (NUMBER)
Etafilcon A (A)Corneal StainingCentral region grade > 04 eyes
Etafilcon A (A)Corneal StainingSuperior region grade > 07 eyes
Etafilcon A (A)Corneal StainingNasal region grade > 02 eyes
Etafilcon A (A)Corneal StainingTemporal region grade > 08 eyes
Etafilcon A (A)Corneal StainingInferior region grade > 034 eyes
Etafilcon A (B)Corneal StainingTemporal region grade > 03 eyes
Etafilcon A (B)Corneal StainingCentral region grade > 06 eyes
Etafilcon A (B)Corneal StainingInferior region grade > 025 eyes
Etafilcon A (B)Corneal StainingNasal region grade > 06 eyes
Etafilcon A (B)Corneal StainingSuperior region grade > 05 eyes
Etafilcon A (C)Corneal StainingInferior region grade > 044 eyes
Etafilcon A (C)Corneal StainingTemporal region grade > 05 eyes
Etafilcon A (C)Corneal StainingSuperior region grade > 03 eyes
Etafilcon A (C)Corneal StainingCentral region grade > 03 eyes
Etafilcon A (C)Corneal StainingNasal region grade > 07 eyes

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026